Philip L Mccarthy

List of Publications by Year
in descending order

127 papers	4,682 citations	218677 26 h-index	110387 64 g-index
128 all docs	128 docs citations	128 times ranked	6013 citing authors

#	Article	IF	Citations
1	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood, 2015, 125, 2068-2074.	1.4	586
2	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. Journal of Clinical Oncology, 2017, 35, 3279-3289.	1.6	535
3	Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood, 2002, 100, 406-414.	1.4	503
4	Increasing Incidence of Chronic Graft-versus-Host Disease inÂAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 266-274.	2.0	331
5	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncology, The, 2014, 15, 333-342.	10.7	256
6	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood, 2017, 130, 1156-1164.	1.4	210
7	Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2015, 21, 1479-1487.	2.0	173
8	Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. Drugs, 2017, 77, 505-520.	10.9	150
9	Î²2 adrenergic receptorâ€“mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. Journal of Clinical Investigation, 2019, 129, 5537-5552.	8.2	141
10	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
11	Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1046-1053.	2.0	133
12	Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age. Biology of Blood and Marrow Transplantation, 2013, 19, 1116-1123.	2.0	104
13	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biology of Blood and Marrow Transplantation, 2018, 24, 1322-1340.	2.0	85
14	Maintenance Treatment and Survival in Patients With Myeloma. JAMA Oncology, 2018, 4, 1389.	7.1	67
15	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biology of Blood and Marrow Transplantation, 2016, 22, 1493-1503.	2.0	55
16	The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica, 2016, 101, 1426-1433.	3.5	53
17	Gaucher's disease and chronic lymphocytic leukemia. Possible pathogenetic link between Gaucher's disease and b-cell proliferations?. Cancer, 1984, 54, 312-314.	4.1	49
18	Housing Temperatureâ€“Induced Stress Is Suppressing Murine Graft-versus-Host Disease through Î²2-Adrenergic Receptor Signaling. Journal of Immunology, 2015, 195, 5045-5054.	0.8	48

#	Article	IF	Citations
19	Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. Blood, 2017, 130, 1585-1596.	1.4	45
20	Î²2-adrenergic receptor signaling regulates metabolic pathways critical to myeloid-derived suppressor cell function within the TME. Cell Reports, 2021, 37, 109883.	6.4	45
21	Update on the role of lenalidomide in patients with multiple myeloma. Therapeutic Advances in Hematology, 2018, 9, 175-190.	2.5	42
22	Discontinuation of Systematic Surveillance and Contact Precautions for Vancomycin-ResistantEnterococcus(VRE) and Its Impact on the Incidence of VREfaeciumBacteremia in Patients with Hematologic Malignancies. Infection Control and Hospital Epidemiology, 2016, 37, 398-403.	1.8	40
23	Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. Blood Advances, 2017, 1, 1056-1066.	5.2	40
24	Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1679-1686.	2.0	37
25	Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. Biology of Blood and Marrow Transplantation, 2015, 21, 55-59.	2.0	34
26	T Cellâ€“Derived CD70 Delivers an Immune Checkpoint Function in Inflammatory T Cell Responses. Journal of Immunology, 2017, 199, 3700-3710.	0.8	34
27	Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. Blood, 2016, 128, 2450-2456.	1.4	32
28	Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. Nature Communications, 2022, 13, 807.	12.8	29
29	Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. Hematology American Society of Hematology Education Program, 2013, 2013, 496-503.	2.5	26
30	A TLR5 Agonist Enhances CD8+T Cell-Mediated Graft-versus-Tumor Effect without Exacerbating Graft-versus-Host Disease. Journal of Immunology, 2012, 189, 4719-4727.	0.8	25
31	Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2015, 21, 793-798.	2.0	23
32	Role of stem cell transplant and maintenance therapy in plasma cell disorders. Hematology American Society of Hematology Education Program, 2016, 2016, 504-511.	2.5	22
33	Granzyme Bâ€“Mediated Damage of CD8+ T Cells Impairs Graft-versus-Tumor Effect. Journal of Immunology, 2013, 190, 1341-1350.	0.8	21
34	Granzyme Bâ€“Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease. Journal of Immunology, 2015, 195, 4514-4523.	0.8	21
35	Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation. Blood, 2018, 131, 2490-2499.	1.4	21
36	Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. Biology of Blood and Marrow Transplantation, 2019, 25, 599-605.	2.0	20

#	Article	IF	Citations
37	Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease. Cytometry Part B - Clinical Cytometry, 2020, 98, 161-173.	1.5	20
38	BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. Biology of Blood and Marrow Transplantation, 2018, 24, 641-648.	2.0	19
39	Blockade of Host Î²2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs. Journal of Immunology, 2018, 200, 2479-2488.	0.8	17
40	Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2020, 26, e7-e15.	2.0	16
41	Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex. Blood Advances, 2017, 1, 1717-1728.	5.2	15
42	Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?. Current Hematologic Malignancy Reports, 2019, 14, 31-38.	2.3	15
43	A phase I/<scp>II</scp> study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance <scp>A061202</scp>). American Journal of Hematology, 2021, 96, 1595-1603.	4.1	15
44	Maintenance Therapy for Multiple Myeloma. Hematology/Oncology Clinics of North America, 2014, 28, 839-859.	2.2	14
45	The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1251-1257.	2.0	14
46	Ascertainment of Unmet Needs and Participation in Health Maintenance and Screening of Adult Hematopoietic Cell Transplantation Survivors Followed in a Formal Survivorship Program. Biology of Blood and Marrow Transplantation, 2017, 23, 1968-1973.	2.0	14
47	VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naiî¨ve Multiple Myeloma (MM).. Blood, 2004, 104, 3463-3463.	1.4	14
48	A CIBMTR Prognostic Model for Progression-Free Survival (PFS) After Autologous Hematopoietic Cell Transplantation (AHCT) for Relapsed or Refractory Hodgkin Lymphoma (HL). Blood, 2011, 118, 499-499.	1.4	14
49	Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell-Associated Encephalopathy (ICE) Score. Biology of Blood and Marrow Transplantation, 2020, 26, e271-e274.	2.0	13
50	Î²2-Adrenergic receptor activation on donor cells ameliorates acute GvHD. JCI Insight, 2020, 5, .	5.0	13
51	Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2019, 25, e89-e97.	2.0	12
52	Comparing thermal stress reduction strategies that influence MDSC accumulation in tumor bearing mice. Cellular Immunology, 2021, 361, 104285.	3.0	12
53	Identification and Utilization of Donor and Recipient Genetic Variants to Predict Survival After HCT: Are We Ready for Primetime?. Current Hematologic Malignancy Reports, 2015, 10, 45-58.	2.3	11
54	Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function. Journal of Immunology, 2017, 199, 336-347.	0.8	11

#	Article	IF	Citations
55	Serine protease inhibitor 6 protects alloreactive T cells from Granzyme B-mediated mitochondrial damage without affecting graft-versus-tumor effect. OncoImmunology, 2018, 7, e1397247.	4.6	11
56	Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. Bone Marrow Transplantation, 2019, 54, 497-507.	2.4	11
57	Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity. Biology of Blood and Marrow Transplantation, 2019, 25, 689-698.	2.0	9
58	Dextramer reagents are effective tools for quantifying CMV antigen-specific T cells from peripheral blood samples. , 2014, , n/a-n/a.		8
59	Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase. Journal of Clinical Oncology, 2018, 36, 2101-2104.	1.6	8
60	Host-Derived Serine Protease Inhibitor 6 Provides Granzyme Bâ€“Independent Protection of Intestinal Epithelial Cells in Murine Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 2397-2408.	2.0	8
61	Validation of genetic associations with acute GVHD and nonrelapse mortality in DISCOVeRY-BMT. Blood Advances, 2019, 3, 2337-2341.	5.2	8
62	Future Directions in Maintenance Therapy in Multiple Myeloma. Journal of Clinical Medicine, 2021, 10, 2261.	2.4	8
63	Genome-Wide Association Analyses Identify Variants in IRF4 Associated With Acute Myeloid Leukemia and Myelodysplastic Syndrome Susceptibility. Frontiers in Genetics, 2021, 12, 554948.	2.3	8
64	Novel genetic variants associated with mortality after unrelated donor allogeneic hematopoietic cell transplantation. EClinicalMedicine, 2021, 40, 101093.	7.1	8
65	Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events.. Blood, 2009, 114, 3416-3416.	1.4	8
66	Wholeâ€body magnetic resonance imaging plus serological followâ€up for early identification of progression in smouldering myeloma patients to prevent development of endâ€organ damage. British Journal of Haematology, 2022, 199, 65-75.	2.5	8
67	Multiple functional variants in the IL1RL1 region are pretransplant markers for risk of GVHD and infection deaths. Blood Advances, 2019, 3, 2512-2524.	5.2	7
68	Combined Donor and Recipient Non-HLA Genotypes Show Evidence of Genome Wide Association with Transplant Related Mortality (TRM) after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (URD-BMT) (DISCOVeRY-BMT study). Blood, 2015, 126, 61-61.	1.4	7
69	Granzyme B Contributes to the Optimal Graft-Versus-Tumor Effect Mediated by Conventional CD4 T Cells. Journal of Immunology Research and Therapy, 2016, 1, 22-28.	1.0	7
70	Population-Based Analysis of Hematologic Malignancy Referrals to a Comprehensive Cancer Center, Referrals for Blood and Marrow Transplantation, and Participation in Clinical Trial, Survey, and Biospecimen Research by Race. Biology of Blood and Marrow Transplantation, 2015, 21, 1488-1494.	2.0	6
71	The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma. Expert Review of Anticancer Therapy, 2019, 19, 889-898.	2.4	6
72	Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients postâ€“unrelated HCT. Blood Advances, 2021, 5, 66-70.	5.2	6

#	Article	IF	Citations
73	Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. Hematology American Society of Hematology Education Program, 2013, 2013, 496-503.	2.5	6
74	High Frequency and Early Onset of Bone Mineral Density Loss Following Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 2011-2011.	1.4	6
75	Histopathologic verification of acute leukemia (AL) in a cohort of 463 post-Chernobyl patients from Belarus, Russia and Ukraine. Leukemia Research, 2004, 28, 1273-1280.	0.8	5
76	Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1369-1374.	2.0	5
77	Quantifying MHC dextramer-induced NFAT activation in antigen-specific T cells as a functional response parameter. Methods, 2017, 112, 75-83.	3.8	5
78	Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?. Current Hematologic Malignancy Reports, 2019, 14, 39-46.	2.3	5
79	Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2020, 26, e247-e255.	2.0	5
80	Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550). Blood, 2019, 134, 4451-4451.	1.4	5
81	Evidence for Heterogeneous Genetic Associations with Acute Lymphoblastic Leukemia (ALL) By Cytogenetics and Sex in High-Risk Patients Treated with Matched Unrelated Donor Allogeneic Blood or Marrow Transplant (URD-BMT). Blood, 2015, 126, 2621-2621.	1.4	5
82	Multiple Myeloma. Hematology/Oncology Clinics of North America, 2014, 28, 1113-1129.	2.2	4
83	Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant. Bone Marrow Transplantation, 2020, 55, 77-85.	2.4	4
84	Low-Level Cytomegalovirus Antigenemia Promotes Protective Cytomegalovirus Antigen-Specific T Cells after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 2147-2154.	2.0	4
85	Serological Response to Vaccination after Autologous Transplantation for Multiple Myeloma Is Associated with Improved Progression-Free and Overall Survival. Transplantation and Cellular Therapy, 2021, 27, 245.e1-245.e8.	1.2	4
86	Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia. Scientific Reports, 2021, 11, 15004.	3.3	4
87	Optimizing the Timing of Allogeneic Blood or Marrow Transplantation (BMT) in a Prospective Cohort of Relapsed or Refractory Acute Myeloid Leukemia (AML). Blood, 2011, 118, 3096-3096.	1.4	4
88	Melflufen: A Next-Generation Nitrogen Mustard. Journal of Clinical Oncology, 2021, 39, 836-839.	1.6	3
89	The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 807-816.	1.2	3
90	Î²2- Adrenergic Signaling Regulates Graft Versus Host Disease after Allogenic Transplantation While Preserving Graft Versus Leukemia Effect. Blood, 2019, 134, 1915-1915.	1.4	3

#	Article	IF	Citations
91	A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022. Expert Review of Anticancer Therapy, 2022, , 1-13.	2.4	3
92	Lenalidomide, bortezomib, and dexamethasone (RVd) Â± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.. Journal of Clinical Oncology, 2022, 40, LBA4-LBA4.	1.6	3
93	Second transplant as a standard for multiple myeloma. Lancet Oncology, The, 2014, 15, 786-788.	10.7	2
94	BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia. Bone Marrow Transplantation, 2018, 53, 651-653.	2.4	2
95	Commentary on â€œIs posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myelomaâ€• by Giovanni Barosi and Robert Peter Gale. Leukemia, 2019, 33, 565-566.	7.2	2
96	Optical Coherence Tomography for Quantifying Human Cutaneous Chronic Graft-versus-Host Disease. Transplantation and Cellular Therapy, 2021, 27, 271.e1-271.e8.	1.2	2
97	Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma. Blood, 2020, 136, 14-15.	1.4	2
98	De Novo and Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: Similarities and Differences in SNP-Array Detected Chromosomal Aberrations in Pre-Transplant Blood Samples. Blood, 2019, 134, 1430-1430.	1.4	2
99	Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT) Tj ETQq1 1 0.784314 rgBT /Over	1.4	2
100	Where Are We Going with Autologous Transplantation for Multiple Myeloma?. Biology of Blood and Marrow Transplantation, 2013, 19, 1532-1533.	2.0	1
101	Replicated Risk Index of Patient Functional Status Prior to Allogeneic Hematopoietic Cell Transplantation Predicts Healthcare Utilization and Survival. Transplantation and Cellular Therapy, 2021, 27, 875.e1-875.e9.	1.2	1
102	Effect of Immune Reconstitution on Survival after Autologous Hematopoietic Cell Transplant for B-Cell Non-Hodgkin Lymphoma. Blood, 2015, 126, 3173-3173.	1.4	1
103	Evolution of Multiparametric Flow Cytometry Testing for Minimal Residual Disease Assessment in Multiple Myeloma and Its Impact on Clinical Outcomes: A Single Institution Experience. Blood, 2016, 128, 2274-2274.	1.4	1
104	Genome-Wide Association Study of Overall and Progression-Free Survival after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT study). Blood, 2015, 126, 397-397.	1.4	1
105	Multiple Myeloma Therapy in Tawam Hospital. First Report from United Arab Emirates (UAE). Blood, 2018, 132, 5652-5652.	1.4	1
106	Immune cell differences between patients in different stages of monoclonal plasma cell disorders.. Journal of Clinical Oncology, 2022, 40, 8065-8065.	1.6	1
107	Continued role for ASCT in multiple myeloma. Lancet Oncology, The, 2015, 16, 1571-1573.	10.7	0
108	Interview with Dr Philip McCarthy. International Journal of Hematologic Oncology, 2017, 6, 97-99.	1.6	0

#	Article	IF	Citations
109	Effect of Bone Marrow Hypoplasia Secondary to Reinduction Therapy for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) on Outcomes after Blood and Marrow Transplantation (BMT).. Blood, 2006, 108, 3033-3033.	1.4	0
110	Fludarabine, Melphalan and Low Dose Total Body Irradiation for Reduced Intensity Conditioning (RIC) Prior to Allogeneic Hematopoietic Cell Transplantation (AlloHCT). Blood, 2011, 118, 4570-4570.	1.4	0
111	Micro Dose Methotrexate (MTX) Is Equivalent to Full Dose MTX and Superior to No MTX for Acute Graft-Versus-Host Disease Prophylaxis. Blood, 2011, 118, 3038-3038.	1.4	0
112	Short Course of Levofloxacin During Neutropenia Prevents Early and Late Bacteremia Episodes After Allogeneic Blood and Marrow Transplantation (alloBMT). Blood, 2012, 120, 4141-4141.	1.4	0
113	Perforin Is Important For Both CD4+ and CD8+ T Cell-Mediated Graft-Versus-Tumor Effect But Plays Differential Roles In CD4+ and CD8+ T Cell Expansion After Allogeneic Transplantation. Blood, 2013, 122, 3255-3255.	1.4	0
114	Analysis Of Immune Cell Populations Before and After Autologous Hematopoietic Stem Cell Transplant For Multiple Myeloma: Association With Early Recovery Of Absolute Lymphocyte Count and Progression-Free Survival. Blood, 2013, 122, 3348-3348.	1.4	0
115	Housing Mice At Sub-Thermoneutral Temperatures Influences Severity Of Gvhd In Mouse Models. Blood, 2013, 122, 5422-5422.	1.4	0
116	Replication of Candidate SNP Survival Analyses and Gene-Based Tests of Association with Survival Outcomes after an Unrelated Donor Blood or Marrow Transplant: Results from the Discovery-BMT Study. Blood, 2016, 128, 71-71.	1.4	0
117	Exome Array Analyses Identify New Genes Influencing Survival Outcomes after HLA-Matched Unrelated Donor Blood and Marrow Transplantation. Blood, 2016, 128, 518-518.	1.4	0
118	Identification of Immune Phenotypes Associated with Improved Progression Free and Overall Survival for Patients with Multiple Myeloma Treated with Autologous Hematopoietic Cell Transplantation. Blood, 2016, 128, 3454-3454.	1.4	0
119	Exome Array Analyses Identify Low-Frequency Germline Variants Associated with Increased Risk of AML in a HLA-Matched Unrelated Donor Blood and Marrow Transplant Population. Blood, 2016, 128, 42-42.	1.4	0
120	Multiple Functional Donor Polymorphisms in IL1RL1 region Associate with Death Due to GvHD or Infection after Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for AML and MDS. Blood, 2018, 132, 312-312.	1.4	0
121	Impact of conditioning regimen on peripheral blood hematopoietic cell transplant. World Journal of Clinical Oncology, 2019, 10, 86-97.	2.3	0
122	Genome Wide Interaction Analysis Identifies Expression Quantitative Trait Loci Associated with Reduced Survival after Reduced Intensity Conditioning HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant. Blood, 2019, 134, 4595-4595.	1.4	0
123	Prediction of Malignant Cell Infiltration Patterns with Texture Features of Biopsy-Correlated Positron Emission Tomography of Osteolytic Lesions in Multiple Myeloma. Blood, 2021, 138, 3997-3997.	1.4	0
124	Clinical Significance of Spatial Heterogeneity in Newly Diagnosed and Relapsed Multiple Myeloma. Blood, 2021, 138, 1607-1607.	1.4	0
125	Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients. Blood, 2021, 138, 4066-4066.	1.4	0
126	Low Intensity Alternative Induction Therapy for Acute Myeloid Leukemia (AML). Real World Experience from Tawam Hospital, United Arab Emirates. Blood, 2021, 138, 4409-4409.	1.4	0

#	Article	IF	Citations
127	Diffuse Large B Cell Lymphoma and Programmed Death-Ligand 1 Expression. a Clinical and Pathological Study of Patients Seen in Tawam Hospital UAE. Blood, 2020, 136, 26-27.	1.4	0